|
Welcome to the Rising Tide Spring Newsletter. In these interesting times, we highlight the human impact and progress of our Seed-financed startup companies. Their stories are most inspiring. Looking forward as usual to your feedback and everlasting cooperation.
|
|
|
|
COVID-19 Social Distancing Solutions
COVID-19 has changed the world. Public spaces need to get methodical about social distancing, and we need to identify and track people with elevated body temperatures. Traditional solutions like camera-based surveillance and app-based contact tracing destroy privacy and are unreliable. Using staff to manually count how many people enter and leave a given area is costly and takes precious personnel away from other important roles.
We believe there is a better solution available right now.
Quanergy’s Flow Management™ platform combines its state-of-the-art 3D LiDAR sensors with its AI-powered QORTEX Perception Software to create the social distancing solutions needed for society to restart and to move forward safely. LiDAR uses light to locate and identify objects with a high degree of accuracy. Quanergy QORTEX Perception Software uses LiDAR data to identify and track individuals throughout without compromising or storing any personal privacy information, unlike camera-based systems, nor requiring user opt-in or sharing of personal data, thus providing a far more effective social distancing solution than alternatives.
|
|
This solution is being rolled out for monitoring social distancing in enterprises, retail spaces, airports, factories, distribution centers, and public transportation.
For more details about the solution, please check this deck and video.
|
|
|
|
Collaboration to Co-Develop a COVID-19 RNA Vaccine
Precision NanoSystems (PNI) AND CanSino Biologics Inc. (CanSinoBIO, HK6185) announced a co-development agreement of a mRNA lipid nanoparticle (mRNA-LNP) vaccine against COVID-19. The parties will leverage PNI's proprietary RNA vaccine platform, comprising of lipid nanoparticle delivery system and the NanoAssemblr® manufacturing technology, to rapidly advance a COVID-19 mRNA-LNP vaccine candidate towards human clinical testing. PNI will be responsible for development of the mRNA-LNP vaccine and CanSinoBIO will be responsible for pre-clinical testing, human clinical trials, regulatory approval, and commercialization.
CanSinoBIO is at the forefront of COVID-19 vaccine development efforts with their candidate Recombinant Novel Coronavirus Vaccine Adenovirus Type 5 Vector (Ad5-nCoV) currently in phase II clinical trial in China. CanSinoBIO recently announced a collaboration with the National Research Council of Canada to initiate clinical testing of the Ad5-nCoV vaccine in Canada.
With over 400 NanoAssemblr® systems placed, PNI supports its customers' drug development and manufacturing efforts in the areas of oncology, infectious diseases, and rare diseases. To offer a complete solution for drug developers, PNI has developed a library of lipid formulations for nucleic acid delivery.
For more details about the solution, please see the company web site here.
|
|
|
UV Device Displays 99.9999% Disinfection of COVID-19 Virus in 1 Second
PuraCath has been partnering and working with a top tier BSL-3 National Laboratory, which has a premiere high containment infectious disease facilities to test its Firefly UV device for the ICU and hospitals with COVID-19 virus.
The preliminary results show that PuraCath’s device has achieved 99.9999% disinfection with SARS-CoV-2 (the virus that is known to cause COVID-19) in just one second. The Firefly UV device can help reduce nurse-to-patient, patient-to-patient, or patient-to-nurse viral transmission in the ICU settings in hospitals. Moreover, in a rapidly paced environment like the ICU, it is critical to be able to disinfect fast and efficiently, like with Firefly.
“We are very excited with this recent partnership with a prestigious National Laboratory and news on rapid disinfection of the COVID-19 virus on our device. We believe that the Firefly can bring substantial clinical benefits and reduced infection transmission in critically ill patients in ICUs and hospitals worldwide,” states Ms. Julia Rasooly, CEO and Founder of PuraCath Medical.
For more details about the solution, please see the company web site here.
|
|
|
Atia Vision Closes Second Tranche of $20M in Series D Financing. Link here
|
|
New fully rebuilt Brave for Android boosts performance across the board compared to prior versions: 5% battery savings along with 3% of both data and CPU savings. Link here.
|
|
|
Castle Named a 2020 “Best Place to Work in the Bay Area”. Link here
|
|
Animoca Brands and Dapper Labs launch new CryptoKitties artist series designed by Momo Wang. Link here
|
|
|
Former Google and Apple Executive Joins Exo Imaging. Link here
|
|
Finaeo: Guide to Remote Work for Financial Advisors. Link here
|
|
|
RBC Signals Announces CEO Christopher Richins Selected for Karman Fellowship Program. Link here
|
|
Teampay Announces New Product Features to Enhance Financial Agility Across a Distributed Workforce. Link here
|
|
- INTERVIEW: Activ Surgical CEO, Todd Usen was interviewed by Joe Mullings, Founder of the Mullings Group. Link here.
- INFORMATIONAL: The Generative Simulation Platform for Construction. Link here.
- WEBINAR: Microfluidic 3D bioprinting and functional characterization of a contractile smooth muscle tissue model. Link here.
- INFORMATIONAL: Messari has announced programming details for its inaugural global virtual event “Mainnet 2020”, sponsored by Bitgo. Link here.
- INFORMATIONAL: California startup Opus 12 aims to help polluters recycle carbon dioxide. Link here.
- WEBINAR: Restart the Economy with 3D LiDAR Social Distancing Solutions. Link here.
- WEBINAR: Roadmap to Innovation, Renewal, and Recovery. Link here.
|
|
|
Disclosure: This presentation is not an offer to sell securities of any investment fund or a solicitation of offers to buy any such securities. Securities of any fund (the “Fund”) managed by Rising Tide Fund Managers, LLC (the “Rising Tide”) are offered to selected investors only by means of a complete offering memorandum and related subscription materials which contain significant additional information about the terms of an investment in the Fund (such documents, the “Offering Documents”). The portfolio companies described herein do not represent all the portfolio companies purchased, sold or recommended for portfolios advised by Rising Tide. The reader should not assume that an investment in the portfolio companies identified were or will be profitable. Past performance is not indicative of future results. Investors should be aware that a loss of investment is possible. The information in this presentation was prepared by Rising Tide and is believed to be reliable. Rising Tide makes no representation as to the accuracy or completeness of such information. Opinions, estimates and projections in this presentation constitute the current judgment of Rising Tide and are subject to change without notice.
|
|
|
|
|
|
